Chemomab Therapeutics Ltd. (CMMB)
NASDAQ: CMMB · Real-Time Price · USD
1.475
-0.065 (-4.22%)
Apr 28, 2026, 4:00 PM EDT - Market closed
Chemomab Therapeutics Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Net Income | -9 | -13.95 | -24.22 | -27.65 | -12.48 | |
| Depreciation & Amortization | 0.07 | 0.05 | 0.07 | 0.06 | 0.03 | |
| Stock-Based Compensation | 0.62 | 0.62 | 1.49 | 3.21 | 2.02 | |
| Other Operating Activities | 0.01 | - | - | - | - | |
| Change in Accounts Receivable | -1.14 | -0.49 | 0.9 | -0.06 | -2.06 | |
| Change in Accounts Payable | -0.18 | 0.12 | -1.17 | 0.35 | 1.18 | |
| Change in Other Net Operating Assets | -1.52 | -1.74 | -0.68 | 3.72 | -1.07 | |
| Operating Cash Flow | -11.13 | -15.39 | -23.61 | -20.37 | -12.37 | |
| Capital Expenditures | -0 | - | -0 | -0.07 | -0.24 | |
| Sale of Property, Plant & Equipment | - | - | - | - | 1 | |
| Investment in Securities | 5.39 | 2.3 | 15.88 | 19.6 | -45.95 | |
| Other Investing Activities | - | - | - | - | 0 | |
| Investing Cash Flow | 5.39 | 2.3 | 15.88 | 19.53 | -45.19 | |
| Issuance of Common Stock | 7.16 | 9.87 | 3.5 | 0.41 | 58.65 | |
| Repurchase of Common Stock | - | - | - | -1.22 | - | |
| Other Financing Activities | - | - | - | - | 2.43 | |
| Financing Cash Flow | 7.16 | 9.87 | 3.5 | -0.81 | 61.07 | |
| Net Cash Flow | 1.42 | -3.22 | -4.23 | -1.65 | 3.51 | |
| Free Cash Flow | -11.13 | -15.39 | -23.61 | -20.44 | -12.61 | |
| Free Cash Flow Per Share | -1.75 | -3.43 | -8.04 | -7.18 | -4.86 | |
| Cash Income Tax Paid | - | - | -0.19 | -0.35 | - | |
| Levered Free Cash Flow | -8.2 | -10.86 | -15.49 | -10.87 | -6.07 | |
| Unlevered Free Cash Flow | -8.2 | -10.86 | -15.49 | -10.87 | -6 | |
| Change in Working Capital | -2.84 | -2.11 | -0.95 | 4.01 | -1.95 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.